T. Rowe Price reports 8.3% stake in QuidelOrtho
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 5,629,965 shares of QuidelOrtho Corp common stock, equal to 8.3% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 5,629,965 shares of QuidelOrtho Corp common stock, equal to 8.3% of the class. The filing lists 5,612,705 shares with sole voting power and 5,629,965 shares with sole dispositive power. The amendment is signed by a Vice President and dated 04/08/2026.
Insights
Large passive holding disclosed: T. Rowe Price holds 8.3% of QuidelOrtho.
T. Rowe Price reports 5,629,965 shares beneficially owned with sole dispositive control, representing 8.3% of the class. Such Schedule 13G/A amendments typically update position counts and ownership percentages rather than signal trading intent.
Track subsequent amendments or Form 13D filings for changes in intent; investor filings and corporate disclosures will show material shifts in ownership or voting plans.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficial ownership financial
sole dispositive power legal
sole voting power legal
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does T. Rowe Price report in QDEL?
Is this a Schedule 13G or 13D filing for QDEL?
Does T. Rowe Price claim beneficial ownership in the filing for QDEL?
When was the Schedule 13G/A signed for QuidelOrtho (QDEL)?
AI-generated analysis. How Rhea-AI works. Not financial advice.